Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors

Next Previous
Trial Profile

Efficacy and Safety of Concizumab prophylaxis in patients with haemophilia A or B with inhibitors

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Concizumab (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Registrational; Therapeutic Use
  • Acronyms explorer7
  • Sponsors Novo Nordisk

Most Recent Events

  • 06 Jun 2025 According to Novo Nordisk media release, data from this trial will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress, June 21-25.
  • 20 Dec 2024 According to Novo Nordisk media release, announced today that the U.S. Food and Drug Administration (FDA) approved Alhemo (concizumab-mtci) injection as a once-daily prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or B with inhibitors FDA approval is based on data from this trial.
  • 03 Dec 2024 According to Novo Nordisk media release, company announced they will presenting data of this trial at the upcoming 66th Annual Meeting and Exposition of the American Society of Hematology (ASH), which will take place from 7 to 10 December 2024 in San Diego, California.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top